ESR1 and breast cancer: Consistent with the lower lymphocytic infiltrate and PD-1/PD-L1 expression, patients with ER+ tumors respond more poorly to immune checkpoint inhibitors than other breast cancer subtypes (Keynote-028, JAVELIN trials) [50,51].